AA
CRVS icon

Ancora Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Ancora Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$801K Buy
54,768
+7,101
+15% +$113K 0.02% 444
2025
Q4 		$367K Buy
47,667
+377
+0.8% +$2.97K 0.01% 606
2025
Q3 		$349K Buy
47,290
+4,183
+10% +$21.4K 0.01% 612
2025
Q2 		$172K Buy
43,107
+5,238
+14% +$19.1K ﹤0.01% 755
2025
Q1 		$120K Hold
37,869
– – ﹤0.01% 819
2024
Q4 		$203K Buy
37,869
+14,584
+63% +$109K ﹤0.01% 706
2024
Q3 		$123K Buy
+23,285
New +$83.6K ﹤0.01% 784

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ancora Advisors's CRVS Position: Q1 2026 in Review

Ancora Advisors increased its Corvus Pharmaceuticals (CRVS) stake by 15% in Q1 2026, buying an estimated $113K and bringing the position to 54,768 shares worth $801K. The position accounts for 0.02% of the portfolio, ranked #444.

Ancora Advisors first reported a position in CRVS in Q3 2024 and has held it in 7 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Ancora Advisors held 54,768 shares of Corvus Pharmaceuticals worth $801K as of Q1 2026.
  • Ancora Advisors bought 7,101 Corvus Pharmaceuticals shares in Q1 2026, an estimated $113K.
  • Corvus Pharmaceuticals made up 0.02% of Ancora Advisors's portfolio in Q1 2026, its #444 holding.
  • Ancora Advisors first reported a position in Corvus Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.